Physician profile
Mazen Jarach
NPI 1962624924
$2,321.31
in general payments reported to CMS, 2019-2025
28 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $104 · 2021: $378 · 2022: $407 · 2023: $288 · 2024: $557 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.51 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $359.54 | 2019-2025 | |
| Abbvie INC. | $263.65 | 2021-2025 | |
| Lilly USA, LLC | $151.94 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $117.40 | 2022-2025 | Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $104.21 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $85.39 | 2023-2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $82.73 | 2019-2025 | Eliquis |
| Allergan, INC. | $70.64 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.57 | 2021-2023 | |
| Glaxosmithkline, LLC. | $66.44 | 2021-2022 | |
| Astellas Pharma US INC | $53.40 | 2021-2023 | Veozah |
| Avanir Pharmaceuticals, INC. | $48.02 | 2021-2022 | |
| Mylan Specialty L.P. | $40.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.80 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.25 | 2024 | Dificid |
| Grt US Holding, INC. | $31.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.52 | 2022 | |
| Pulmonx Corporation | $21.10 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Novo Nordisk INC | $18.71 | 2021 | |
| Radius Health, INC. | $17.61 | 2021 | |
| Acadia Pharmaceuticals INC | $16.15 | 2022 | |
| Lundbeck LLC | $16.08 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $16.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.74 | 2025 | Rexulti |
| Inogen, INC. | $14.45 | 2022 | |
| Ucb, INC. | $14.15 | 2022 | |
| Seqirus USA INC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Jarach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.